Project Details
Description
This research project examines the function of carbohydrate chains that are O-linked to leukocyte cell-
surface glycoproteins. By acting as the natural ligands of the selectin family of adhesion molecules, these
glycoproteins control the rates of leukocyte adhesion in the human vasculature during normal immune
response, inflammatory diseases and certain types of cardiovascular disorders. It is widely believed that
controlling the rate of leukocyte adhesion in vascular disorders can lead to new therapies to combat these
ailments. Thus, in the current proposal, we evaluate two mechanisms for controlling selectin-ligand binding.
In Aim 1, we develop and test the ability of unique molecules based on an unusual disaccharide
carbohydrate structure (GalNAc(31,3GalNAca-O-Methyl) to competitively inhibit selectin binding interactions
with its ligand. Our preliminary data suggests that this disaccharide alone can bind P- selectin. We also
demonstrate that appropriate modification of this unit can dramatically enhance the binding affinity of the
resulting carbohydrate for selectins, when compared with the prototypic selectin ligand sialyl Lewis-X. In Aim
2, we test an approach where small-molecule metabolic inhibitors are designed based on the structure of
monosaccharides that compose natural selectin ligands. These modified monosaccharidesare fed to cells in
order to interfere with the biosynthesis of specific carbohydrate epitopes on the glycoprotein ligands of
selectins. More specifically, these molecules are directed to alter either the core or terminal residues of
glycans expressed by an important leukocyte selectin-ligand called PSGL-1 (P-selectin glycoprotein ligand-
1). We evaluate the ability and mechanism by which these chemical inhibitors permeate cells, engage and
modify glycan biosynthetic pathways and inhibit cell adhesion. In Aim 3, to complement the experimental
work above, a Systems Biology based mathematical model is developed to simulate biochemical networks
that regulate O-glycan biosynthesis in leukocytes. Many of the assumptions in this mathematical model are
experimentally validated. Diverse experimental methods are applied to accomplish the above three aims.
These include cell adhesion studies under controlled flow, in vivo experiments in a mouse model of acute
inflammation, western blot analysis, molecular biology based approaches, flow cytometry, surface plasmon
resonance and liquid chromatography. In the long run, we anticipate that small-molecule selectin-antagonists
will be identified from this work that may aid future drug design. Mathematical models developed will
enhance the application of metabolic engineering principles in the area of biological chemistry. Such analysis
can also provide the rationale for the chemical synthesis of new inhibitors and for interpretation of
experimental observations.
| Status | Finished |
|---|---|
| Effective start/end date | 12/1/05 → 06/3/11 |
Funding
- National Heart Lung and Blood Institute: $1,189,482.33
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.